Entrada Therapeutics, Inc. entered into an Amendment to License Agreement and an Amendment to Sublicense Agreement with Vertex Pharmaceuticals Incorporated, receiving an upfront payment of $223.7 million and eligible for up to $485.0 million in milestone payments.